Qiagen NV (QGEN)
43.75
+0.02
(+0.05%)
USD |
NYSE |
Jun 18, 16:00
42.12
-1.63
(-3.73%)
Pre-Market: 07:54
Qiagen Enterprise Value: 10.32B for June 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 18, 2024 | 10.32B |
| June 17, 2024 | 10.31B |
| June 14, 2024 | 10.00B |
| June 13, 2024 | 10.23B |
| June 12, 2024 | 10.42B |
| June 11, 2024 | 10.36B |
| June 10, 2024 | 10.57B |
| June 07, 2024 | 10.56B |
| June 06, 2024 | 10.58B |
| June 05, 2024 | 10.51B |
| June 04, 2024 | 10.30B |
| June 03, 2024 | 10.37B |
| May 31, 2024 | 10.21B |
| May 30, 2024 | 10.07B |
| May 29, 2024 | 10.06B |
| May 28, 2024 | 10.15B |
| May 24, 2024 | 10.31B |
| May 23, 2024 | 10.19B |
| May 22, 2024 | 10.26B |
| May 21, 2024 | 10.60B |
| May 20, 2024 | 10.70B |
| May 17, 2024 | 10.75B |
| May 16, 2024 | 10.81B |
| May 15, 2024 | 10.76B |
| May 14, 2024 | 10.68B |
| Date | Value |
|---|---|
| May 13, 2024 | 10.44B |
| May 10, 2024 | 10.28B |
| May 09, 2024 | 10.28B |
| May 08, 2024 | 10.14B |
| May 07, 2024 | 10.14B |
| May 06, 2024 | 10.06B |
| May 03, 2024 | 10.15B |
| May 02, 2024 | 10.08B |
| May 01, 2024 | 10.11B |
| April 30, 2024 | 10.00B |
| April 29, 2024 | 9.994B |
| April 26, 2024 | 9.850B |
| April 25, 2024 | 9.724B |
| April 24, 2024 | 9.821B |
| April 23, 2024 | 9.903B |
| April 22, 2024 | 9.755B |
| April 19, 2024 | 9.484B |
| April 18, 2024 | 9.367B |
| April 17, 2024 | 9.313B |
| April 16, 2024 | 9.333B |
| April 15, 2024 | 9.411B |
| April 12, 2024 | 9.524B |
| April 11, 2024 | 9.744B |
| April 10, 2024 | 9.746B |
| April 09, 2024 | 9.921B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.718B
Minimum
Oct 08 2019
14.04B
Maximum
Sep 02 2021
11.14B
Average
11.03B
Median
Jun 03 2020
Enterprise Value Benchmarks
| MoonLake Immunotherapeutics | 1.946B |
| LENZ Therapeutics Inc | 254.51M |
| Thermo Fisher Scientific Inc | 245.73B |
| argenx SE | 19.28B |
| uniQure NV | -231.69M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 80.67M |
| Revenue (Quarterly) | 458.80M |
| Total Expenses (Quarterly) | 360.55M |
| EPS Diluted (Quarterly) | 0.3636 |
| Gross Profit Margin (Quarterly) | 63.42% |
| Profit Margin (Quarterly) | 17.58% |
| Earnings Yield | 3.45% |
| Operating Earnings Yield | 4.49% |
| Normalized Earnings Yield | 3.714 |